Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Accounts Payables (2016 - 2025)

Iradimed (IRMD) has disclosed Accounts Payables for 13 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 66.61% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 66.61% increase, with the full-year FY2024 number at $1.9 million, up 2.12% from a year prior.
  • Accounts Payables was $2.3 million for Q3 2025 at Iradimed, up from $1.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $2.8 million in Q3 2023 to a low of $618217.0 in Q1 2021.
  • A 5-year average of $1.5 million and a median of $1.4 million in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: soared 210.43% in 2023, then crashed 56.07% in 2024.
  • Iradimed's Accounts Payables stood at $782903.0 in 2021, then soared by 129.83% to $1.8 million in 2022, then rose by 3.21% to $1.9 million in 2023, then increased by 2.12% to $1.9 million in 2024, then increased by 23.05% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Accounts Payables are $2.3 million (Q3 2025), $1.9 million (Q2 2025), and $2.6 million (Q1 2025).